The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand 1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.本發明係提供與T-細胞共抑制劑配體程序性死亡配體1(PD-L1)蛋白結合之抗體，及使用方法。在本發明的各種實施例中，此等抗體為與PD-L1結合之全人類抗體。在特定的實施例中，本發明係提供多-專一性抗原結合分子，其係包括一與PD-L1結合之第一結合專一性，以及一與腫瘤細胞抗原、感染細胞特異性抗原或T-細胞共抑制劑結合之第二結合專一性。在某些實施例中，本發明之抗體可用於抑制或中和PD-L1活性，因此提供一治療疾病或病症，例如癌症或病毒感染之方法。
